See more : Rise Gold Corp. (RISE.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Quanta, Inc. (QNTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quanta, Inc., a leading company in the Household & Personal Products industry within the Consumer Defensive sector.
You may be interested
- American Airlines Group Inc. (A1G.DE) Income Statement Analysis – Financial Results
- Lime Chemicals Limited (LIMECHM.BO) Income Statement Analysis – Financial Results
- Naturgy Energy Group, S.A. (GASNF) Income Statement Analysis – Financial Results
- Global Net Lease, Inc. (GNL-PA) Income Statement Analysis – Financial Results
- IMAX China Holding, Inc. (1970.HK) Income Statement Analysis – Financial Results
Quanta, Inc. (QNTA)
About Quanta, Inc.
Quanta, Inc., an applied science company, provides pharmaceutical, nutraceutical, topical relief, and cosmetic products in the United States. The company offers contract research services, including research, development, and production of pharmaceutical-grade products, as well as clinical evidence-based nutraceuticals utilizing patented polarization technology. It also manufactures and distributes consumer wellness products in areas of pain relief, beauty, and general wellness. The company was founded in 2016 and is headquartered in Burbank, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Revenue | 673.41K | 1.16M | 1.27M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 143.42K | 281.27K | 303.72K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 529.98K | 876.85K | 965.27K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 78.70% | 75.71% | 76.07% | 0.00% | 0.00% | 0.00% |
| Research & Development | 453.50K | 452.44K | 351.67K | 85.00K | 74.00K | 4.40K |
| General & Administrative | 7.88M | 5.56M | 6.10M | 93.95K | 54.99K | 14.86K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.88M | 5.56M | 6.10M | 93.95K | 54.99K | 14.86K |
| Other Expenses | 390.71K | -381.08K | -238.40K | 0.00 | 4.00K | 0.00 |
| Operating Expenses | 8.33M | 6.01M | 6.45M | 178.95K | 132.99K | 19.26K |
| Cost & Expenses | 8.48M | 6.29M | 6.76M | 178.95K | 132.99K | 19.26K |
| Interest Income | 0.00 | 0.00 | 37.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 584.78K | 1.27M | 226.24K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 153.06K | 342.89K | 261.07K | 161.14K | 4.00K | 22.82K |
| EBITDA | -7.65M | -5.39M | -5.23M | -178.95K | 0.00 | 0.00 |
| EBITDA Ratio | -1,135.93% | -413.42% | -411.88% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.80M | -5.13M | -5.49M | -178.95K | -132.99K | -19.26K |
| Operating Income Ratio | -1,158.66% | -443.03% | -432.46% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -450.65K | -2.78M | -299.54K | 0.00 | 311.95K | 0.00 |
| Income Before Tax | -8.25M | -8.16M | -5.79M | -178.95K | -132.99K | -19.26K |
| Income Before Tax Ratio | -1,225.58% | -704.98% | -456.06% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 584.78K | 1.27M | 226.24K | 357.91K | 265.99K | 0.00 |
| Net Income | -8.84M | -9.43M | -6.01M | -178.95K | -132.99K | -19.26K |
| Net Income Ratio | -1,312.42% | -814.50% | -473.89% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.16 | -0.14 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.04 | -0.16 | -0.14 | -0.01 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 224.02M | 59.91M | 42.81M | 19.78M | 22.00M | 22.00M |
| Weighted Avg Shares Out (Dil) | 224.02M | 59.91M | 42.81M | 19.78M | 22.00M | 22.00M |
Medolife Rx Launches Ad Campaign With Tony Hawk, Sees Immediate Positive Results
BURBANK, CA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today the...
Medolife Rx Clarifies April 13, 2021 Press Release
BURBANK, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife" or the “Company”), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC...
Medolife Rx Recaps Successful Attendance at Tony Hawk Event; Saw Significant Product Exposure
BURBANK, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), today recapped their...
Medolife Rx Reports Second Quarter 2021 Financial and Operational Results, Schedules Conference Call With Investment Community
BURBANK, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today...
Medolife Rx Schedules Investor Webcast for Tuesday, July 27, 2021
BURBANK, CA, July 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it will hold...
Medolife Rx Announces Donation of Escozine to Heath Clinic in Dominican Republic for Use on Growing COVID-19 Positive Patient Population
BURBANK, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced...
Medolife Rx Clinical Observations Demonstrates Effectiveness of Escozine in Complementary Use with COVID-19 Vaccines
BURBANK, Calif., July 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced...
Medolife Rx Enters Partnership Agreement with Leading International Distributor, Brings Products to Mexico
BURBANK, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced...
FDA Accepts COVID-19 Clinical Study and Advises on Next Steps for Pre-IND Filing by Medolife Rx
BURBANK, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated biopharmaceutical company with R&D, manufacturing, and consumer products, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today...
Source: https://incomestatements.info
Category: Stock Reports